Navigation Links
Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease
Date:8/5/2008

The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients.

Membranous nephropathy (also known as membranous glomerulopathy) is one of the most common immune-mediated kidney diseases, and is thought to be caused by autoimmune reactions against the kidney. The disease, which is characterized by the loss of large amounts of protein in the urine, leads to impaired kidney function that may ultimately require dialysis or renal transplantation.

A variety of immunosuppressive drugs have been tested to inhibit the production of the antibodies that attack the kidneys during the progression of membranous nephropathy, but their effects have been inconsistent. These therapies also can cause significant toxicity and can suppress a patient's immune system, exposing the patient to an increased risk of infections and illnesses.

A new drug called rituximab selectively depletes B lymphocytes, the cells that produce the damaging autoantibodies of membranous nephropathy. The drug was initially developed as a cancer treatment for patients with B cell lymphoma, but kidney researchers have shown that this drug also is safe and reduces the amount of protein lost in the urine due to membranous nephropathy. These same researchers, led by Piero Ruggenenti, MD, of the Negri Bergamo Laboratories in Bergamo, Italy, have now provided evidence that rituximab actually reduces the amount of kidney injury in patients with the disease.

In this study, Dr. Ruggenenti and his colleagues treated 50 patients with membranous nephropathy with rituximab. The investigators found that 10 of the patients event
'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study suggests brain tumors need treatment with multiple targeted drugs
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Research suggests targeted treatment strategies for lupus
4. S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
6. Gleevec, the targeted cancer pill, delivers more good news to patients
7. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
8. Light powered platinum more targeted and 80 times more powerful than similar cancer treatments
9. A major step toward a more targeted treatment for auto-immune diseases?
10. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
11. New study of targeted therapies for breast cancer -- model for global clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... January 22, 2015 Four years since the release ... which coincided with the marriage of Avasa & Matthew Love – ... which is scheduled for release through White Swan Records on February ... there is a sacred path available to all of us to ...
(Date:1/22/2015)... a famous dress online store for wedding dresses and other ... of wedding dresses , and launches a site-wide women’s dress ... on your big day; the wedding gown is the most ... find the most suitable wedding dress. Now, we are proud ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2
... NASHVILLE, Tenn., Nov. 10 Healthcare Realty,Trust Incorporated (NYSE: ... quarter,ended September 30, 2008. Funds from operations ("FFO") per ... same period in 2007. FFO,per diluted common share totaled ... with the prior year,s $1.13. FFO would have been ...
... patients or women who want to delay childbirth , , ... the ability to freeze and transplant ovaries, a development ... therapy. , "We can transplant ovaries without any loss ... normally whether it,s fresh or frozen," said co-researcher Dr. ...
... Omega Protein Corporation,(NYSE: OME ), the nation,s ... products, today reported net income of $3.1 million (17,cents ... to net income of,$7.2 million (42 cents a share) ... (Logo: http://www.newscom.com/cgi-bin/prnh/20030516/OMEGALOGO ), Revenues for the third ...
... Inc. ( www.infotrieve.com ), the global leader in business service solutions ... Content SCM software solution at the biopharma company UCB, headquartered in ... ... EON) November 10, 2008 -- Content SCM is Infotrieve,s revolutionary ...
... Thermage, Inc.,(Nasdaq: THRM ), a leader in ... results for the third quarter ended,September 30, 2008. Reliant ... quarter., Thermage revenue for the third quarter of ... million for the third quarter of 2007. Domestic,revenue decreased ...
... LAKE FOREST, Ill., Nov. 10 Hospira, Inc.,(NYSE: ... medication delivery,company, announced today that Ken Meyers has ... Development. In this,capacity, he will lead the global ... high-performance culture and organizational excellence.,Meyers succeeds Henry Weishaar, ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Third Quarter Results 2Health News:Healthcare Realty Trust Announces Third Quarter Results 3Health News:Healthcare Realty Trust Announces Third Quarter Results 4Health News:Healthcare Realty Trust Announces Third Quarter Results 5Health News:Healthcare Realty Trust Announces Third Quarter Results 6Health News:Healthcare Realty Trust Announces Third Quarter Results 7Health News:Healthcare Realty Trust Announces Third Quarter Results 8Health News:Healthcare Realty Trust Announces Third Quarter Results 9Health News:Freezing Ovaries Preserves Fertility, Scientists Report 2Health News:Freezing Ovaries Preserves Fertility, Scientists Report 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 2Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 3Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 4Health News:Omega Protein Reports 17 Cents Per Share Third Quarter Profit 5Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 2Health News: Infotrieve's Revolutionary Content SCM Solution Launched at UCB 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 2Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 3Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 4Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 5Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 6Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 7Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 8Health News:Thermage Reports Third Quarter Financial Results and Provides Information Regarding Reliant's Results 9Health News:Hospira Names Ken Meyers to Lead Human Resources 2
(Date:1/23/2015)... 23, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 ... communication has been the topic of fascination since the era ... and the Soviet Russia. Earlier even a small ...
(Date:1/23/2015)... BETHESDA, Md. , Jan. 23, 2015  Northwest Biotherapeutics, Inc. ... developing DCVax® personalized immune therapies for operable and inoperable solid ... will present at the 7 th Annual Phacilitate Immunotherapy ... NW Bio,s presentation at Phacilitate will take place on January ...
(Date:1/23/2015)... Rose, baseball,s all-time hits leader, is the new spokesperson for ... Pharma has announced. "Pete,s a Hall of Famer ... on board with Myoflex," said Ducere Pharma Chief Executive Officer ... is known across all generations. The passion and intensity that ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... TOKYO, October 6 Sosei Group Corporation,("Sosei"; TSE ... R&D Ltd., its wholly owned UK subsidiary, has entered,into ... of AD 923, an optimised,sublingual formulation of the opioid ... well as to the device for drug administration to,Pharmasol ...
... The following letter is being released by CEL-SCI ... , Dear Fellow Shareholders: , After FDA had communicated several ... trial with our proposed H1N1 treatment for hospitalized H1N1 patients, ... With this in mind, we have asked one of our ...
Cached Medicine Technology:Sosei Assigns AD 923 Assets to Pharmasol 2CEL-SCI Corporation Releases Letter to Shareholders 2CEL-SCI Corporation Releases Letter to Shareholders 3CEL-SCI Corporation Releases Letter to Shareholders 4CEL-SCI Corporation Releases Letter to Shareholders 5CEL-SCI Corporation Releases Letter to Shareholders 6CEL-SCI Corporation Releases Letter to Shareholders 7
... fixation with the Pennig Minifixator, combines the advantage ... procedure. Soft tissue dissection is not necessary, since ... now, external fixation in the hand has required ... of cases (Asche and Burny) because of the ...
The Medium External Fixator has a double-rod frame, medium Combination Clamp medium Multi-Pin Clamp, and Carbon Fiber Rods. Rod Attachment for Medium Multi-Pin Clamp allows second rod to be added....
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
Medicine Products: